BRST5:Acinic cell carcinoma: Difference between revisions

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
[checked revision][checked revision]
← Older edit
VisualWikitext
No edit summary
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 26: Line 26:
|}
|}


==WHO Essential and Desirable Genetic Diagnostic Criteria==
{| class="wikitable"
|+
|WHO Essential Criteria (Genetics)*
|
|-
|WHO Desirable Criteria (Genetics)*
|
|-
|Other Classification
|
|}
<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
==Related Terminology==
==Related Terminology==
<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>
 
{| class="wikitable"
{| class="wikitable"
|+
|+
|Acceptable
|Acceptable
|
|N/A
|-
|-
|Not Recommended
|Not Recommended
|
|N/A
|}
|}


Line 73: Line 60:
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
!Chr #!!'''Gain, Loss, Amp, LOH'''!!'''Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]'''!!'''Relevant Gene(s)'''
!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T'''
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!'''Clinical Relevance Details/Other Notes'''
!Clinical Relevance Details/Other Notes
|-
|-
|
|
Line 92: Line 79:
!Chromosomal Pattern
!Chromosomal Pattern
!Molecular Pathogenesis
!Molecular Pathogenesis
!'''Prevalence -'''
!Prevalence -  
'''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
Common >20%, Recurrent 5-20% or Rare <5% (Disease)
!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T'''
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!'''Clinical Relevance Details/Other Notes'''
!Clinical Relevance Details/Other Notes
|-
|-
|
|
Line 109: Line 96:
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
!Gene!!'''Genetic Alteration'''!!'''Tumor Suppressor Gene, Oncogene, Other'''!!'''Prevalence -'''
!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
'''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
Common >20%, Recurrent 5-20% or Rare <5% (Disease)
!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T  '''
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T  
!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!'''Clinical Relevance Details/Other Notes'''
!Clinical Relevance Details/Other Notes
|-
|-
|''TP53''
|''TP53''
Line 160: Line 147:
https://www.pathologyoutlines.com/topic/breastmalignantaciniccellcarcinoma.html
https://www.pathologyoutlines.com/topic/breastmalignantaciniccellcarcinoma.html
==References==
==References==
<br />
<br /><references />
 
==Notes==
==Notes==
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership|''<u>Associate Editor</u>'']] or other CCGA representative.  When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.  
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership|''<u>Associate Editor</u>'']] or other CCGA representative.  When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.  

Latest revision as of 17:29, 11 December 2025


Breast Tumours (WHO Classification, 5th ed.)

Katherine Geiersbach, MD

WHO Classification of Disease

Structure Disease
Book Breast Tumours (5th ed.)
Category Epithelial tumours of the breast
Family Rare and salivary gland-type tumours: Introduction
Type Acinic cell carcinoma
Subtype(s) N/A

Related Terminology

Acceptable N/A
Not Recommended N/A

Gene Rearrangements


Driver Gene Fusion(s) and Common Partner Genes Molecular Pathogenesis Typical Chromosomal Alteration(s) Prevalence -Common >20%, Recurrent 5-20% or Rare <5% (Disease) Diagnostic, Prognostic, and Therapeutic Significance - D, P, T Established Clinical Significance Per Guidelines - Yes or No (Source) Clinical Relevance Details/Other Notes

Individual Region Genomic Gain/Loss/LOH


Chr # Gain, Loss, Amp, LOH Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size] Relevant Gene(s) Diagnostic, Prognostic, and Therapeutic Significance - D, P, T Established Clinical Significance Per Guidelines - Yes or No (Source) Clinical Relevance Details/Other Notes

Characteristic Chromosomal or Other Global Mutational Patterns

Often high complexity genomic copy number profile, similar to other triple negative breast cancers, in contrast to other rare salivary gland type neoplasia of the breast.[1][2]

Chromosomal Pattern Molecular Pathogenesis Prevalence -

Common >20%, Recurrent 5-20% or Rare <5% (Disease)

Diagnostic, Prognostic, and Therapeutic Significance - D, P, T Established Clinical Significance Per Guidelines - Yes or No (Source) Clinical Relevance Details/Other Notes

Gene Mutations (SNV/INDEL)


Gene Genetic Alteration Tumor Suppressor Gene, Oncogene, Other Prevalence -

Common >20%, Recurrent 5-20% or Rare <5% (Disease)

Diagnostic, Prognostic, and Therapeutic Significance - D, P, T   Established Clinical Significance Per Guidelines - Yes or No (Source) Clinical Relevance Details/Other Notes
TP53 SNV, deletion Tumor suppressor gene Common P Similar to other triple negative breast cancers[1][3][4][5]
PIK3CA SNV Oncogene Recurrent

Note: A more extensive list of mutations can be found in cBioportal, COSMIC, and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.

Epigenomic Alterations


Genes and Main Pathways Involved

Put your text here and fill in the table (Instructions: Please include references throughout the table. Do not delete the table.)

Gene; Genetic Alteration Pathway Pathophysiologic Outcome
TP53 DNA damage response DNA damage, genomic instability
PIK3CA PI3K/Akt/mTOR pathway Increased cell growth and proliferation

Genetic Diagnostic Testing Methods


Familial Forms


Additional Information


Links

https://www.pathologyoutlines.com/topic/breastmalignantaciniccellcarcinoma.html

References


  1. ↑ 1.0 1.1 Geyer, Felipe C.; et al. (2017-10). "The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions". The American Journal of Pathology. 187 (10): 2139–2151. doi:10.1016/j.ajpath.2017.03.016. ISSN 1525-2191. PMC 5809519. PMID 28736315. Check date values in: |date= (help)
  2. ↑ Guerini-Rocco, Elena; et al. (2015-10). "The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study". The Journal of Pathology. 237 (2): 166–178. doi:10.1002/path.4566. ISSN 1096-9896. PMC 5011405. PMID 26011570. Check date values in: |date= (help)
  3. ↑ Beca, Francisco; et al. (2019-12). "Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast". Histopathology. 75 (6): 931–937. doi:10.1111/his.13962. ISSN 1365-2559. PMC 6878125. PMID 31361912. Check date values in: |date= (help)
  4. ↑ Geyer, Felipe C.; et al. (2017-01). "Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family". Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 30 (1): 69–84. doi:10.1038/modpathol.2016.161. ISSN 1530-0285. PMC 5221420. PMID 27713419. Check date values in: |date= (help)
  5. ↑ Ajkunic, Azra; et al. (2022-12). "Acinic cell carcinoma of the breast: A comprehensive review". Breast (Edinburgh, Scotland). 66: 208–216. doi:10.1016/j.breast.2022.10.012. ISSN 1532-3080. PMC 9636467 Check |pmc= value (help). PMID 36332545 Check |pmid= value (help). Check date values in: |date= (help)

Notes

*Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the Associate Editor or other CCGA representative.  When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.

Prior Author(s): *Citation of this Page: “Acinic cell carcinoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 12/11/2025, https://ccga.io/index.php/BRST5:Acinic cell carcinoma.

Retrieved from "https://test.ccga.io/index.php?title=BRST5:Acinic_cell_carcinoma&oldid=19709"